
AbCellera Biologics ABCL
$ 3.45
1.32%
Annual report 2025
added 02-24-2026
AbCellera Biologics DSO Ratio 2011-2026 | ABCL
Annual DSO Ratio AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 | 202 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 202 | 173 | 188 |
Quarterly DSO Ratio AbCellera Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 720 | 357 | 1.03 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.2 | 43.2 | 5.46 | - | - | 3.67 | 8.85 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 K | 3.67 | 274 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Heron Therapeutics
HRTX
|
198 | $ 0.79 | 1.9 % | $ 132 M | ||
|
Altimmune
ALT
|
7.85 K | $ 3.44 | 2.99 % | $ 303 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 218.03 | -1.74 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Incyte Corporation
INCY
|
66.6 | $ 90.43 | -0.21 % | $ 17.7 B | ||
|
Inovio Pharmaceuticals
INO
|
1.91 K | $ 1.54 | -2.41 % | $ 34.1 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
KalVista Pharmaceuticals
KALV
|
475 | $ 16.82 | -1.06 % | $ 835 M | ||
|
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | ||
|
Kamada Ltd.
KMDA
|
103 | $ 8.27 | 0.24 % | $ 260 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
60.8 | $ 2.13 | 1.67 % | $ 199 M | ||
|
Karyopharm Therapeutics
KPTI
|
72.5 | $ 7.11 | -6.82 % | $ 866 K | ||
|
Denali Therapeutics
DNLI
|
1.89 | $ 20.99 | 4.07 % | $ 3.45 B | ||
|
Keros Therapeutics
KROS
|
4.72 | $ 11.16 | 1.82 % | $ 415 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.35 | 2.48 % | $ 722 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
81.5 K | - | -5.98 % | $ 34.1 M |